NeuroMetrix to Present at 5th Annual OneMedForum San Francisco 2012 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 3, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N.
NeuroMetrix Reports Commercial Milestone 100th NC-stat® DPNCheck™ Order WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 28, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced the achievement
NeuroMetrix to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 29, 2011-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of
NeuroMetrix, Inc. Announces Date for 2011 Third Quarter Financial Results Conference Call WALTHAM, Mass., Oct 20, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 third quarter financial results before the opening of the market on October 27, 2011.
NeuroMetrix Names Kenneth J. Snow, M.D. as Chief Medical Officer WALTHAM, Mass., Oct 04, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Kenneth J. Snow, M.D. as Chief Medical Officer. The appointment was effective October 3, 2011.
NeuroMetrix Reports Compliance With NASDAQ Listing Requirements WALTHAM, Mass., Sep 19, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has received a letter from The NASDAQ Stock Market LLC ("NASDAQ") indicating that it has regained compliance with the minimum bid
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference WALTHAM, Mass., Sep 07, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today announced that Shai N.
